---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-068589"
form_type: "8-K"
ticker: "CRMD"
cik: "0001410098"
company_name: "CorMedix Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:17:11.029139+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# CorMedix Q2 net loss $14.2M; DefenCath sales $0.8M initial, outpatient QTD $5.2M

## Summary
- Q2 net loss $14.2M ($0.25/share) vs $11.3M loss ($0.25/share) a year ago, driven by higher operating expenses.
- DefenCath net sales $0.8M for partial quarter since April 15 inpatient launch; outpatient QTD sales $5.2M as of Aug 13.
- Operating expenses $15.6M in Q2 (+32% YoY) from commercial launch costs; R&D down 86% post-approval.
- Cash and short-term investments $45.6M at June 30, sufficient for at least 12 months.
- Submitted TPN study protocol to FDA; patient enrollment expected to begin Q1 2025.

## SEC filing metadata
- accession: 0001213900-24-068589
- form_type: 8-K
- ticker: CRMD
- cik: 0001410098
- company_name: CorMedix Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1410098/000121390024068589/0001213900-24-068589-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1410098/000121390024068589/ea0211338-8k_cormed.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-068589
- JSON: https://secwatch.observer/filing/0001213900-24-068589.json
- Plain text: https://secwatch.observer/filing/0001213900-24-068589.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.